Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK

Proteomics - Clinical Applications

Volumn 5, Issue 5-6, 2011, Pages 281-288

  Blanco Colio, Luis M ^a   Martín Ventura, Jose L ^a   Carrero, Juan J ^b   Yilmaz, Mahmut I ^c   Moreno, Juan A ^a   Gómez Guerrero, Carmen ^a   Ortiz, Alberto ^a   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Biomarkers; Cardiovascular disease; STWEAK

Indexed keywords

AMLODIPINE; BIOLOGICAL MARKER; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; VALSARTAN;

CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

APOPTOSIS; BIOLOGICAL MARKERS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; PROTEOMICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79957597843     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000102     Document Type: Review

References (43)

1. Wang, T. J., Gona, P., Larson, M. G. et al., Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 2006, 355, 2631-2639.
2. Blanco-Colio, L. M., Martín-Ventura, J. L., Vivanco, F., Michel, J. B. et al., Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc. Res. 2006, 72, 18-29.
3. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
4. Arab, S., Gramolini, A. O., Ping, P. et al., Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J. Am. Coll. Cardiol. 2006, 48, 1733-1741.
5. Tuñón, J., Martín-Ventura, J. L., Blanco-Colio, L. M., Lorenzo, O. et al., Proteomic strategies in the search of new biomarkers in atherothrombosis. J. Am. Coll. Cardiol. 2010, 55, 2009-2016.
6. Hlatky, M. A., Greenland, P., Arnett, D. K., Ballantyne, C. M. et al., Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119, 2408-2416.
7. Kiehntopf, M., Siegmund, R., Deufel, T., Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin. Chem. Lab. Med. 2007, 45, 1435-1449.
8. Blanco-Colio, L. M., Martín-Ventura, J. L., Muñóz-García, B., Orbe, J. et al., Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 916-922.
9. Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu, Y. M. et al., TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 1997, 272, 32401-32410.
10. Winkles, J. A., The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 2008, 37, 173-178.
11. Muñoz-Garcia, B., Martin-Ventura, J. L., Martinez, E., Sanchez, S. et al., Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques modulation by atorvastatin. Stroke 2006, 37, 2044-2053.
12. Muñoz-García, B., Moreno, J. A., López-Franco, O., Sanz, A. B. et al., Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 2061-2068.
13. -/- mice and inhibits macrophage lipid uptake in vitro. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 2021-2027.
14. Muñoz-García, B., Madrigal-Matute, J., Moreno, J. A., Martin-Ventura, J. L. et al., TWEAK/Fn14 interaction enhances PAI-1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc. Res. 2011, 89, 225-233.
15. Ortiz, A., Sanz, A. B., Muñoz-García, B., Moreno, J. A. et al., Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev. 2009, 20, 251-258.
16. Kralisch, S., Ziegelmeier, M., Bachmann, A., Seeger, J. et al., Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008, 199, 440-444.
17. Carrero, J. J., Ortiz, A., Qureshi, A. R., Martín-Ventura, J. L. et al., Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2009, 4, 110-118.
18. Yilmaz, M. I., Carrero, J. J., Ortiz, A., Martín-Ventura, J. L. et al., Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 1716-1723.
19. Jelić-Ivanović, Z., Bujisić, N., Spasić, S., Bogavac-Stanojević, N. et al., Circulating sTWEAK improves the prediction of coronary artery disease. Clin. Biochem. 2009, 42, 1381-1386.
20. Chorianopoulos, E., Jarr, K., Steen, H., Giannitsis, E. et al., Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010, 211, 322-326.
21. Chorianopoulos, E., Rosenberg, M., Zugck, C., Wolf, J. et al., Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur. J. Heart Fail. 2009, 11, 1050-1056.
22. Moreno, J. A., Dejouvencel, T., Labreuche, J., Smadja, D. M. et al., Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1253-1262.
23. Martín-Ventura, J. L., Lindholt, J. S., Moreno, J. A., Vega de Céniga, M. et al., Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011, 214, 486-489.
24. Kim, C. X., Bailey, K. R., Klee, G. G., Ellington, A. A. et al., Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteómica markers of arteriosclerosis study. PLoS One 2010, 5, e9065.
25. Yilmaz, M. I., Carrero, J. J., Martín-Ventura, J. L., Sonmez, A. et al., Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin. J. Am. Soc. Nephrol. 2010, 5, 1174-1181.
26. Bots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., Grobbee, D. E., Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997, 128, 262-269.
27. Libby, P., Ridker, PM., Maseri, A., Inflammation and atherosclerosis. Circulation 2002, 105, 1135-1143.
28. Widlansky, M. E., Gokce, N., Keaney, J. F., Jr., Vita, J. A., The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. 2003, 42, 1149-1160.
29. Vita, J. A., Keaney, J. F., Jr., Endothelial function: a barometer for cardiovascular risk? Circulation 2002, 106, 640-642.
30. Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J. et al., Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340, 1111-1115.
31. Joannides, R., Haefeli, W. E., Linder, L., Richard, V. et al., Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91, 1314-1319.
32. Mullen, M. J., Kharbanda, R. K., Cross, J., Donald, A. E. et al., Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ. Res. 2001, 88, 145-151.
33. Gocke, N., Keaney, J. F., Hunter, L. M., Watkins, M. T. et al., Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002, 105, 1567-1572.
34. Kuvin, J. T., Patel, R. R., Sliney, K. A., Pandian, N. G. et al., Peripheral vascular endothelial function testing as a non-invasive indicator of coronary artery disease. J. Am. Coll. Cardiol. 2001, 38, 1843-1849.
35. Endemann, D. H., Schiffrin, E. L., Endothelial dysfunction. J. Am. Soc. Nephrol. 2004, 15, 1983-1992.
36. Suwaidi, J. A., Hamasaki, S., Higano, S. T., Nishimura, R. A. et al., Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101, 948-954.
37. Foley, R. N., Parfrey, P. S., Sarnak, M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998, 32, S112-S119.
38. Tonelli, M., Pfeffer, M. A., Kidney disease and cardiovascular risk. Annu. Rev. Med. 2007, 58, 123-139.
39. Carrero, J. J., Stenvinkel, P., Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin. J. Am. Soc. Nephrol. 2009, 4, S49-S55.
40. Tonelli, M., Pfeffer, M. A., Kidney disease and cardiovascular risk. Ann. Rev. Med. 2007, 58, 123-139.
41. Stenvinkel, P., Carrero, J. J., Axelsson, J., Lindholm, B. et al., Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin. J. Am. Soc. Nephrol. 2008, 3, 505-521.
42. Kalantar-Zadeh, K., Block, G., Humphreys, M. H., Kopple, J. D., Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003, 63, 793-808.
43. Richter, B., Rychli, K., Hohensinner, P. J., Berger, R. et al., Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 2010, 213, 545-548.